By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Qiagen today announced a deal with Eli Lilly to develop a companion diagnostic for an investigational compound the drug manufacturer is developing for blood cancers.

The deal calls for Qiagen to develop, manufacture, and co-commercialize a test for Eli Lilly's JAK2 inhibitor, which targets the Janus kinase 2, or JAK2, gene, which is associated with myeloproliferative neoplasms, a variety of blood cancers that cause abnormal growth in blood cells.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

What happens to scientific papers when certain journals are no longer published? Some scientists are trying to make sure they don't disappear forever.

A study in Microbiome finds that heavy drinkers have an unhealthy mix of bacteria in their mouths.

Doctors and patients are still trying to figure out what role at-home genetic testing should play in healthcare, Newsweek says.

In Genome Research this week, mismatch repair deficiency in C. elegans, retracing transcriptions start site evolution in the human genome, and more. 

May
15
Sponsored by
Tecan

This webinar will discuss how an algorithm-driven synthetic biology system can enable engineering of biological systems for a range of applications.

Jun
20
Sponsored by
PerkinElmer

In this webinar, Michael Quail of the R&D Sequencing team at the Wellcome Trust Sanger Institute will provide an expert perspective on library prep for next-generation sequencing.

Jun
28
Sponsored by
PerkinElmer

This webinar will review a standardized, high-throughput, and fully automated library prep protocol for human metagenomic analysis.